INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47401, 10774, 'Dicyclomine', 'Esophagitis, Peptic', 'Therapy with dicyclomine is contraindicated in patients with reflux esophagitis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47402, 10775, 'Dicyclomine', 'Esophagitis, Peptic', 'Therapy with dicyclomine is contraindicated in patients with reflux esophagitis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47403, 27350, 'Dicyclomine', 'Esophagitis, Peptic', 'Therapy with dicyclomine is contraindicated in patients with reflux esophagitis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47404, 27353, 'Dicyclomine', 'Esophagitis, Peptic', 'Therapy with dicyclomine is contraindicated in patients with reflux esophagitis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47405, 10774, 'Dicyclomine', 'Colitis, Ulcerative', 'Therapy with dicyclomine is contraindicated in patients with severe ulcerative colitis.  Antimuscarinic agents, such as dicyclomine may suppress intestinal motility and produce paralytic ileus with resultant precipitation of toxic megacolon.  Antimuscarinic agents should be administered cautiously to patients with ulcerative colitis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47406, 10775, 'Dicyclomine', 'Colitis, Ulcerative', 'Therapy with dicyclomine is contraindicated in patients with severe ulcerative colitis.  Antimuscarinic agents, such as dicyclomine may suppress intestinal motility and produce paralytic ileus with resultant precipitation of toxic megacolon.  Antimuscarinic agents should be administered cautiously to patients with ulcerative colitis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47407, 27350, 'Dicyclomine', 'Colitis, Ulcerative', 'Therapy with dicyclomine is contraindicated in patients with severe ulcerative colitis.  Antimuscarinic agents, such as dicyclomine may suppress intestinal motility and produce paralytic ileus with resultant precipitation of toxic megacolon.  Antimuscarinic agents should be administered cautiously to patients with ulcerative colitis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47408, 27353, 'Dicyclomine', 'Colitis, Ulcerative', 'Therapy with dicyclomine is contraindicated in patients with severe ulcerative colitis.  Antimuscarinic agents, such as dicyclomine may suppress intestinal motility and produce paralytic ileus with resultant precipitation of toxic megacolon.  Antimuscarinic agents should be administered cautiously to patients with ulcerative colitis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47409, 10774, 'Dicyclomine', 'Coronary Artery Disease', 'Antimuscarinic agents block vagal inhibition of the SA nodal pacemaker.  These agents should be administered cautiously in patients with tachycardia, congestive heart failure, or coronary artery disease.  Premature ventricular depolarization or ventricular tachycardia or fibrillation associated with antimuscarinic drugs is rare.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47410, 10775, 'Dicyclomine', 'Coronary Artery Disease', 'Antimuscarinic agents block vagal inhibition of the SA nodal pacemaker.  These agents should be administered cautiously in patients with tachycardia, congestive heart failure, or coronary artery disease.  Premature ventricular depolarization or ventricular tachycardia or fibrillation associated with antimuscarinic drugs is rare.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47411, 27350, 'Dicyclomine', 'Coronary Artery Disease', 'Antimuscarinic agents block vagal inhibition of the SA nodal pacemaker.  These agents should be administered cautiously in patients with tachycardia, congestive heart failure, or coronary artery disease.  Premature ventricular depolarization or ventricular tachycardia or fibrillation associated with antimuscarinic drugs is rare.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47412, 27353, 'Dicyclomine', 'Coronary Artery Disease', 'Antimuscarinic agents block vagal inhibition of the SA nodal pacemaker.  These agents should be administered cautiously in patients with tachycardia, congestive heart failure, or coronary artery disease.  Premature ventricular depolarization or ventricular tachycardia or fibrillation associated with antimuscarinic drugs is rare.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47413, 10774, 'Dicyclomine', 'Gastroesophageal Reflux', 'Antimuscarinic agents decrease gastric motility and relax the lower esophageal sphincter which promotes gastric retention and can aggravate reflux.  These drugs should be administered cautiously in patients with gastroesophageal reflux or hiatal hernia associated with reflux esophagitis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47414, 10775, 'Dicyclomine', 'Gastroesophageal Reflux', 'Antimuscarinic agents decrease gastric motility and relax the lower esophageal sphincter which promotes gastric retention and can aggravate reflux.  These drugs should be administered cautiously in patients with gastroesophageal reflux or hiatal hernia associated with reflux esophagitis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47415, 27350, 'Dicyclomine', 'Gastroesophageal Reflux', 'Antimuscarinic agents decrease gastric motility and relax the lower esophageal sphincter which promotes gastric retention and can aggravate reflux.  These drugs should be administered cautiously in patients with gastroesophageal reflux or hiatal hernia associated with reflux esophagitis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47416, 27353, 'Dicyclomine', 'Gastroesophageal Reflux', 'Antimuscarinic agents decrease gastric motility and relax the lower esophageal sphincter which promotes gastric retention and can aggravate reflux.  These drugs should be administered cautiously in patients with gastroesophageal reflux or hiatal hernia associated with reflux esophagitis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47417, 10774, 'Dicyclomine', 'Psychotic Disorders', 'Toxic psychosis manifested as confusion, disorientation, agitation, excitation, memory impairment, delusions and hallucinations may develop at toxic and therapeutic dosages of antimuscarinic agents.  Therapy with these agents should be administered cautiously in patients with mental disorders receiving antimuscarinic agents for control of drug-induced extrapyramidal effects, especially at the beginning of therapy or during dosage adjustment.  Psychiatric deterioration and psychotic flare-ups have also been reported following withdrawal of therapy.  Symptoms include delusions, hallucinations, aggression or violent behavior, and suicidal tendencies.  In high dosages, antimuscarinic agents may sometimes produce euphorigenic effects.  For this reason, it can be a drug of abuse.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47418, 10775, 'Dicyclomine', 'Psychotic Disorders', 'Toxic psychosis manifested as confusion, disorientation, agitation, excitation, memory impairment, delusions and hallucinations may develop at toxic and therapeutic dosages of antimuscarinic agents.  Therapy with these agents should be administered cautiously in patients with mental disorders receiving antimuscarinic agents for control of drug-induced extrapyramidal effects, especially at the beginning of therapy or during dosage adjustment.  Psychiatric deterioration and psychotic flare-ups have also been reported following withdrawal of therapy.  Symptoms include delusions, hallucinations, aggression or violent behavior, and suicidal tendencies.  In high dosages, antimuscarinic agents may sometimes produce euphorigenic effects.  For this reason, it can be a drug of abuse.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47419, 27350, 'Dicyclomine', 'Psychotic Disorders', 'Toxic psychosis manifested as confusion, disorientation, agitation, excitation, memory impairment, delusions and hallucinations may develop at toxic and therapeutic dosages of antimuscarinic agents.  Therapy with these agents should be administered cautiously in patients with mental disorders receiving antimuscarinic agents for control of drug-induced extrapyramidal effects, especially at the beginning of therapy or during dosage adjustment.  Psychiatric deterioration and psychotic flare-ups have also been reported following withdrawal of therapy.  Symptoms include delusions, hallucinations, aggression or violent behavior, and suicidal tendencies.  In high dosages, antimuscarinic agents may sometimes produce euphorigenic effects.  For this reason, it can be a drug of abuse.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47420, 27353, 'Dicyclomine', 'Psychotic Disorders', 'Toxic psychosis manifested as confusion, disorientation, agitation, excitation, memory impairment, delusions and hallucinations may develop at toxic and therapeutic dosages of antimuscarinic agents.  Therapy with these agents should be administered cautiously in patients with mental disorders receiving antimuscarinic agents for control of drug-induced extrapyramidal effects, especially at the beginning of therapy or during dosage adjustment.  Psychiatric deterioration and psychotic flare-ups have also been reported following withdrawal of therapy.  Symptoms include delusions, hallucinations, aggression or violent behavior, and suicidal tendencies.  In high dosages, antimuscarinic agents may sometimes produce euphorigenic effects.  For this reason, it can be a drug of abuse.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47421, 10774, 'Dicyclomine', 'Hepatic Insufficiency', 'Effects of hepatic impairment on pharmacokinetics, safety and efficacy of dicyclomine have not been studied.  Dicyclomine should be administered with caution in patients with hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47422, 10775, 'Dicyclomine', 'Hepatic Insufficiency', 'Effects of hepatic impairment on pharmacokinetics, safety and efficacy of dicyclomine have not been studied.  Dicyclomine should be administered with caution in patients with hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47423, 27350, 'Dicyclomine', 'Hepatic Insufficiency', 'Effects of hepatic impairment on pharmacokinetics, safety and efficacy of dicyclomine have not been studied.  Dicyclomine should be administered with caution in patients with hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47424, 27353, 'Dicyclomine', 'Hepatic Insufficiency', 'Effects of hepatic impairment on pharmacokinetics, safety and efficacy of dicyclomine have not been studied.  Dicyclomine should be administered with caution in patients with hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47425, 10774, 'Dicyclomine', 'Hyperthyroidism', 'Caution is recommended when using dicyclomine in patients with hyperthyroidism.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47426, 10775, 'Dicyclomine', 'Hyperthyroidism', 'Caution is recommended when using dicyclomine in patients with hyperthyroidism.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47427, 27350, 'Dicyclomine', 'Hyperthyroidism', 'Caution is recommended when using dicyclomine in patients with hyperthyroidism.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47428, 27353, 'Dicyclomine', 'Hyperthyroidism', 'Caution is recommended when using dicyclomine in patients with hyperthyroidism.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47429, 10774, 'Dicyclomine', 'Kidney Diseases', 'Effects of renal impairment on pharmacokinetics, safety and efficacy of dicyclomine have not been studied.  Dicyclomine is substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function.  Dicyclomine should be administered with caution in patients with renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47430, 10775, 'Dicyclomine', 'Kidney Diseases', 'Effects of renal impairment on pharmacokinetics, safety and efficacy of dicyclomine have not been studied.  Dicyclomine is substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function.  Dicyclomine should be administered with caution in patients with renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47431, 27350, 'Dicyclomine', 'Kidney Diseases', 'Effects of renal impairment on pharmacokinetics, safety and efficacy of dicyclomine have not been studied.  Dicyclomine is substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function.  Dicyclomine should be administered with caution in patients with renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47432, 27353, 'Dicyclomine', 'Kidney Diseases', 'Effects of renal impairment on pharmacokinetics, safety and efficacy of dicyclomine have not been studied.  Dicyclomine is substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function.  Dicyclomine should be administered with caution in patients with renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47433, 10774, 'Dicyclomine', 'Hypertension', 'Cardiovascular effects of anticholinergics may exacerbate hypertension.  Therapy with anticholinergic agents should be administered cautiously in patients with hypertension.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47434, 10775, 'Dicyclomine', 'Hypertension', 'Cardiovascular effects of anticholinergics may exacerbate hypertension.  Therapy with anticholinergic agents should be administered cautiously in patients with hypertension.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47435, 27350, 'Dicyclomine', 'Hypertension', 'Cardiovascular effects of anticholinergics may exacerbate hypertension.  Therapy with anticholinergic agents should be administered cautiously in patients with hypertension.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47436, 27353, 'Dicyclomine', 'Hypertension', 'Cardiovascular effects of anticholinergics may exacerbate hypertension.  Therapy with anticholinergic agents should be administered cautiously in patients with hypertension.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47437, 10774, 'Dicyclomine', 'Fever', 'Atropine-like agents may increase the risk of hyperthermia in patients with fever by producing anhidrosis.  Therapy with atropine-like agents should be administered cautiously in febrile patients.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47438, 10775, 'Dicyclomine', 'Fever', 'Atropine-like agents may increase the risk of hyperthermia in patients with fever by producing anhidrosis.  Therapy with atropine-like agents should be administered cautiously in febrile patients.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47439, 27350, 'Dicyclomine', 'Fever', 'Atropine-like agents may increase the risk of hyperthermia in patients with fever by producing anhidrosis.  Therapy with atropine-like agents should be administered cautiously in febrile patients.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47440, 27353, 'Dicyclomine', 'Fever', 'Atropine-like agents may increase the risk of hyperthermia in patients with fever by producing anhidrosis.  Therapy with atropine-like agents should be administered cautiously in febrile patients.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47441, 0, 'Didanosine', 'Kidney Diseases', 'Didanosine (ddI) is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for ddI-related toxicity due to decreased drug clearance.  Therapy with ddI should be administered cautiously at reduced dosages in patients with renal impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47442, 0, 'Didanosine', 'Bone Marrow Failure Disorders', 'The nucleoside reverse transcriptase inhibitors, didanosine (ddI), zalcitabine (ddC) and stavudine (d4T), may infrequently cause bone marrow suppression at recommended dosages.  Anemia, leukopenia, thrombocytopenia and neutropenia have been reported.  Therapy with these agents should be administered cautiously in patients with preexisting bone marrow depression or blood dyscrasias.  Routine blood counts are recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47443, 0, 'Didanosine', 'Liver Diseases', 'Hepatotoxicity including lactic acidosis, severe hepatomegaly with steatosis, fulminant hepatitis, and hepatic failure has been associated with the use of some nucleoside reverse transcriptase inhibitors (NRTIs) alone or in combination with other antiretroviral agents.  Therapy with NRTIs should be administered cautiously in patients with preexisting liver disease, a history of alcohol abuse, or hepatitis.  Therapy should be suspended if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity occur.  The use of abacavir is contraindicated in patients with moderate to severe hepatic impairment as its safety and efficacy has not been established on these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47444, 0, 'Didanosine', 'Pancreatitis', 'The reverse transcriptase inhibitors, didanosine (ddI), zalcitabine (ddC), stavudine (d4T) and lamivudine (3TC), may cause pancreatitis.  The incidence is generally low but is approximately 7% with ddI, and up to 15% in pediatric patients given 3TC.  Patients with a history of or known risk factors for pancreatitis, such as alcohol abuse or hypertriglyceridemia, should be monitored closely during therapy with these agents.  Therapy should be discontinued at the first signs or symptoms suggestive of pancreatitis (e.g., nausea, vomiting, abdominal pain, hyperamylasemia with dysglycemia, rising triglycerides, decreasing serum calcium), and preferably permanently discontinued if clinical pancreatitis develops.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47445, 0, 'Didanosine', 'Peripheral Nervous System Diseases', 'The nucleoside reverse transcriptase inhibitors, didanosine (ddI), zalcitabine (ddC), and stavudine (d4T), may commonly cause dose-related peripheral neuropathy, particularly in patients with advanced HIV disease.  Usually, the neuropathy resolves slowly following prompt discontinuation of therapy, but it can be irreversible.  These agents should be administered cautiously to patients with a history of neuropathy and avoided in patients with existing polyneuropathy.  Therapy may be reinstituted following resolution of symptoms in patients who have previously experienced neuropathy with these drugs, but reduced dosages are recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47446, 0, 'Didanosine', 'Hyperuricemia', 'Didanosine (ddI) may infrequently cause hyperuricemia.  Patients with preexisting hyperuricemia or gout should be monitored for exacerbation of condition during ddI therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47447, 0, 'Didanosine', 'Phenylketonurias', 'Videx (brand of didanosine, or ddI) chewable/dispersable buffered tablets contain 36.5 mg of phenylalanine per each 25, 50, 100, and 150 mg tablet.  The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e. phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47448, 0, 'Didanosine', 'Heart Failure', 'Didanosine (ddI) formulations have a high sodium content.  There are 265 mg of sodium per tablet and 1380 mg per packet of powder for oral solution, which may be of concern in patients with conditions that may be adversely affected by excessive amounts of sodium, such as congestive heart failure, hypertension, and fluid retention.  Each tablet also contains 8.6 mEq of magnesium.  Patients with significant renal impairment may not tolerate these loads.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47449, 0, 'Diflorasone (topical)', 'Diabetes Mellitus', 'Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Systemic absorption of topical corticosteroids may occur depending on the vehicle and concentration of the preparation, the size of the application area, the integrity of the skin, and the duration of administration.  Use of occlusive dressings over the applied areas may also increase percutaneous absorption.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47450, 0, 'Diflorasone (topical)', 'Diaper Rash', 'Topical corticosteroids, especially the potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol), are generally not recommended for use in the treatment of diaper rash.  Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are usually at the greatest risk for systemic toxicity such as adrenal suppression, Cushing''s syndrome and intracranial hypertension because of their larger skin surface to body mass ratios.  If topical corticosteroids are necessary to treat diaper rash, medium- to low-potency agents should preferably be used, and parents should be advised not to put tight-fitting diapers or plastic pants over the rash, since occlusion of treated area may increase percutaneous drug absorption.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47451, 0, 'Diflorasone (topical)', 'Adrenocortical Hyperfunction', 'The use of topical corticosteroids may precipitate or aggravate conditions of hyperadrenocorticism.  Systemic absorption of these agents can produce reversible hypothalamic-pituitary-adrenal axis suppression.  Systemic absorption, depends on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  Patients with an altered skin barrier or liver failure are also at increased risk.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during topical corticosteroid therapy may indicate excessive use.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47452, 0, 'Diflorasone (topical)', 'Infections', 'Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Clinically significant local as well as systemic immunosuppressant and anti-inflammatory effects may occur, which can cause or exacerbate an infection.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  Therapy with topical corticosteroids should be administered cautiously in patients with latent or active infections, particularly if a potent agent is used on a large area for prolonged periods or if occlusive dressings are used.  Effective antimicrobial therapy or other appropriate treatment should be instituted to treat the infection.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  Occlusive dressings should not be used in patients with skin infection.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47453, 0, 'Diflorasone (topical)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure, especially when potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) are used in the periorbital area.  Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47454, 0, 'Dihydroergotamine', 'Coronary Vasospasm', 'The use of ergot alkaloids is contraindicated in patients with conditions predisposing them to vasospastic reactions, including, ischemic heart disease (angina, history of myocardial infarction, silent ischemia), peripheral vascular disease, sepsis, shock, vascular surgery, uncontrolled hypertension, and severely impaired hepatic or renal function.  The vasoconstriction produced be ergot alkaloids may exacerbate these conditions.  Ergot alkaloids may cause vasospastic reactions other than coronary artery vasospasm such as peripheral vascular reactions, and colonic ischemia, causing muscle pains, numbness, coldness, pallor, and cyanosis of the digits.  In patients with compromised circulation, persistent vasospasm may result in gangrene or death.  Nitroprusside and heparin have been used to treat ergotamine- induced severe vasoconstriction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47455, 4205, 'Diiodohydroxyquinoline', 'Liver Diseases', 'The use of iodoquinol is contraindicated in patients with hepatic damage.  Iodoquinol is a halogenated 8-hydroxyquinolone that may have a prolonged effect in patients with liver dysfunction.  High dosages of iodoquinol have been associated with optic neuritis, optic atrophy, and peripheral neuropathy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47456, 4205, 'Diiodohydroxyquinoline', 'Peripheral Nervous System Diseases', 'The use of high dosages or prolonged therapy with iodoquinol has been associated with the development of peripheral neuropathy.  Therapy with iodoquinol should be administered cautiously in patients with peripheral neuropathy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47457, 4205, 'Diiodohydroxyquinoline', 'Vision Disorders', 'The use of iodoquinol has been associated with optic neuritis and optic atrophy when given in high dosages for prolonged periods.  Optic atrophy has been reported mostly in children treated for acrodermatitis enteropathica at daily dosages between 1300 to 3600 mg for up to two years.  Visual deterioration may be irreversible.  Therapy with iodoquinol should be administered cautiously in patients with or predisposed to visual defects.  Some clinicians also recommend not using iodoquinol and related agents in pediatric patients under 12 years of age.  Long-term therapy should be avoided in all patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47458, 4205, 'Diiodohydroxyquinoline', 'Thyroid Diseases', 'Protein-bound serum iodine levels may be increased during treatment with iodoquinol and may, therefore, interfere with certain thyroid function tests.  Therapy with iodoquinol should be administered cautiously to patients with thyroid disease.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47459, 0, 'Dimercaprol', 'Liver Diseases', 'The use of dimercaprol is contraindicated in patients with impaired hepatic function, except for arsenic- associated jaundice.  Dimercaprol, not complexed to heavy metals, is metabolized by the liver to inactive forms in patients with normal hepatic function.  Hepatic impairment decreases the  metabolism of dimercaprol and can result in elimination of potentially nephrotoxic dimercaprol as well as increased CNS toxicity and hypertension.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47460, 0, 'Dimercaprol', 'Kidney Diseases', 'Dimercaprol is primarily eliminated by the kidney complexed with a heavy metal (lead, arsenic, mercury, gold).  Dimercaprol and heavy metals are nephrotoxic and dissociate at an acid pH.  Urinary alkalinization during dimercaprol therapy is necessary.  The serum concentration of dimercaprol is elevated in patients with oliguria and CNS toxicity and hypertension are possible.  Dimercaprol should be discontinued or used only with extreme caution if acute renal insufficiency develops during therapy.  Therapy with dimercaprol should be administered very cautiously and dosages reduced in patients with oliguria.  Close clinical monitoring of urine pH and renal function is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47461, 0, 'Dimercaprol', 'Peanut Hypersensitivity', 'Dimercaprol ampules are formulated with peanut oil.  Peanut oil may cause allergic reactions in some individuals.  Physicians should use caution in prescribing dimercaprol ampules for peanut-sensitive patients.  Medication and equipment necessary to treat allergic reactions should be available if the product is administered to peanut-allergic patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47462, 0, 'Dimercaprol', 'Glucosephosphate Dehydrogenase Deficiency', 'Dimercaprol-associated hemolysis has been reported in patients with glucose-6-phosphate dehydrogenase deficiency.  Therapy with dimercaprol should be administered with caution in patients with G6PD deficiency.  Clinical monitoring of erythropoietic function including hemolysis is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47463, 0, 'Dimercaprol', 'Hypertension', 'Dose-related increase in systolic and diastolic blood pressure, with or without accompanying tachycardia, is the most frequently reported adverse effect of dimercaprol therapy.  Blood pressure may rise 15 to 30 minutes following injection and usually returns to normal within 2 hours.  Therapy with dimercaprol should be administered cautiously in patients with hypertension.  Clinical monitoring of blood pressure is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47464, 102, 'Alteplase', 'Hemorrhagic Disorders', 'The use of thrombolytics is contraindicated in patients with an active bleed (internal), trauma/surgery (recent CPR/intracranial/intraspinal surgery within 2 months), bleeding diathesis, history of cerebrovascular (CV) accident, intracranial defect (aneurysm, arteriovenous malformation, neoplasm), or severe uncontrolled arterial hypertension (SBP>180/DBP>110).  Risk versus benefit should be carefully considered in the following conditions and thrombolytic therapy administered with caution in patients with recent (10 days) serious GI bleed or recent (10 days) surgical procedure (coronary bypass graft, obstetrical delivery, organ biopsy, puncture of noncompressible vessel), left heart thrombus, subacute bacterial endocarditis, hemostatic defect, CV disease, diabetic hemorrhagic retinopathy, or pregnancy.  Clinical monitoring of hematopoietic, bleeding and coagulation functions is recommended prior to initiation of thrombolytic therapy.  Measures of fibrinolytic activity and/or coagulation functions during infusion do not correlate with efficacy or risk of bleeding.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47465, 13412, 'Alteplase', 'Hemorrhagic Disorders', 'The use of thrombolytics is contraindicated in patients with an active bleed (internal), trauma/surgery (recent CPR/intracranial/intraspinal surgery within 2 months), bleeding diathesis, history of cerebrovascular (CV) accident, intracranial defect (aneurysm, arteriovenous malformation, neoplasm), or severe uncontrolled arterial hypertension (SBP>180/DBP>110).  Risk versus benefit should be carefully considered in the following conditions and thrombolytic therapy administered with caution in patients with recent (10 days) serious GI bleed or recent (10 days) surgical procedure (coronary bypass graft, obstetrical delivery, organ biopsy, puncture of noncompressible vessel), left heart thrombus, subacute bacterial endocarditis, hemostatic defect, CV disease, diabetic hemorrhagic retinopathy, or pregnancy.  Clinical monitoring of hematopoietic, bleeding and coagulation functions is recommended prior to initiation of thrombolytic therapy.  Measures of fibrinolytic activity and/or coagulation functions during infusion do not correlate with efficacy or risk of bleeding.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47466, 5824, 'Dimethyl fumarate', 'Infections', 'Serious cases of herpes zoster have occurred in patients treated with dimethyl fumarate; patients should be monitored for signs/symptoms of herpes zoster while on dimethyl fumarate.  Other serious opportunistic infections have occurred with dimethyl fumarate, including cases of serious viral, fungal, and bacterial infections.  Patients with signs/symptoms consistent with any of these infections should undergo prompt diagnostic evaluation and receive appropriate treatment.  Withholding dimethyl fumarate treatment in patients with herpes zoster or other serious infections until the infection has resolved should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47467, 22278, 'Dimethyl fumarate', 'Infections', 'Serious cases of herpes zoster have occurred in patients treated with dimethyl fumarate; patients should be monitored for signs/symptoms of herpes zoster while on dimethyl fumarate.  Other serious opportunistic infections have occurred with dimethyl fumarate, including cases of serious viral, fungal, and bacterial infections.  Patients with signs/symptoms consistent with any of these infections should undergo prompt diagnostic evaluation and receive appropriate treatment.  Withholding dimethyl fumarate treatment in patients with herpes zoster or other serious infections until the infection has resolved should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47468, 22279, 'Dimethyl fumarate', 'Infections', 'Serious cases of herpes zoster have occurred in patients treated with dimethyl fumarate; patients should be monitored for signs/symptoms of herpes zoster while on dimethyl fumarate.  Other serious opportunistic infections have occurred with dimethyl fumarate, including cases of serious viral, fungal, and bacterial infections.  Patients with signs/symptoms consistent with any of these infections should undergo prompt diagnostic evaluation and receive appropriate treatment.  Withholding dimethyl fumarate treatment in patients with herpes zoster or other serious infections until the infection has resolved should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47469, 22324, 'Dimethyl fumarate', 'Infections', 'Serious cases of herpes zoster have occurred in patients treated with dimethyl fumarate; patients should be monitored for signs/symptoms of herpes zoster while on dimethyl fumarate.  Other serious opportunistic infections have occurred with dimethyl fumarate, including cases of serious viral, fungal, and bacterial infections.  Patients with signs/symptoms consistent with any of these infections should undergo prompt diagnostic evaluation and receive appropriate treatment.  Withholding dimethyl fumarate treatment in patients with herpes zoster or other serious infections until the infection has resolved should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47470, 22325, 'Dimethyl fumarate', 'Infections', 'Serious cases of herpes zoster have occurred in patients treated with dimethyl fumarate; patients should be monitored for signs/symptoms of herpes zoster while on dimethyl fumarate.  Other serious opportunistic infections have occurred with dimethyl fumarate, including cases of serious viral, fungal, and bacterial infections.  Patients with signs/symptoms consistent with any of these infections should undergo prompt diagnostic evaluation and receive appropriate treatment.  Withholding dimethyl fumarate treatment in patients with herpes zoster or other serious infections until the infection has resolved should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47471, 27964, 'Dimethyl fumarate', 'Infections', 'Serious cases of herpes zoster have occurred in patients treated with dimethyl fumarate; patients should be monitored for signs/symptoms of herpes zoster while on dimethyl fumarate.  Other serious opportunistic infections have occurred with dimethyl fumarate, including cases of serious viral, fungal, and bacterial infections.  Patients with signs/symptoms consistent with any of these infections should undergo prompt diagnostic evaluation and receive appropriate treatment.  Withholding dimethyl fumarate treatment in patients with herpes zoster or other serious infections until the infection has resolved should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47472, 27965, 'Dimethyl fumarate', 'Infections', 'Serious cases of herpes zoster have occurred in patients treated with dimethyl fumarate; patients should be monitored for signs/symptoms of herpes zoster while on dimethyl fumarate.  Other serious opportunistic infections have occurred with dimethyl fumarate, including cases of serious viral, fungal, and bacterial infections.  Patients with signs/symptoms consistent with any of these infections should undergo prompt diagnostic evaluation and receive appropriate treatment.  Withholding dimethyl fumarate treatment in patients with herpes zoster or other serious infections until the infection has resolved should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47473, 5824, 'Dimethyl fumarate', 'Liver Failure', 'Dimethyl fumarate has not been studied in patients with liver dysfunction; although no dosage adjustment is needed, caution is recommended when using dimethyl fumarate in these patients.  Clinically significant cases of liver injury have been reported in patients treated with dimethyl fumarate in the postmarketing setting.  Signs/symptoms of liver injury, including elevation of serum aminotransferases to greater than 5-fold the upper limit of normal (ULN) and elevation of total bilirubin to greater than 2-fold ULN have been observed; these abnormalities resolved upon treatment discontinuation.  Elevations of hepatic transaminases (most no greater than 3 times ULN) were observed during controlled trials.  Serum aminotransferase, alkaline phosphatase, and total bilirubin levels should be obtained prior to and during treatment with dimethyl fumarate, as clinically indicated.  Therapy should be discontinued if clinically significant liver injury induced by dimethyl fumarate is suspected.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47474, 22278, 'Dimethyl fumarate', 'Liver Failure', 'Dimethyl fumarate has not been studied in patients with liver dysfunction; although no dosage adjustment is needed, caution is recommended when using dimethyl fumarate in these patients.  Clinically significant cases of liver injury have been reported in patients treated with dimethyl fumarate in the postmarketing setting.  Signs/symptoms of liver injury, including elevation of serum aminotransferases to greater than 5-fold the upper limit of normal (ULN) and elevation of total bilirubin to greater than 2-fold ULN have been observed; these abnormalities resolved upon treatment discontinuation.  Elevations of hepatic transaminases (most no greater than 3 times ULN) were observed during controlled trials.  Serum aminotransferase, alkaline phosphatase, and total bilirubin levels should be obtained prior to and during treatment with dimethyl fumarate, as clinically indicated.  Therapy should be discontinued if clinically significant liver injury induced by dimethyl fumarate is suspected.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47475, 22279, 'Dimethyl fumarate', 'Liver Failure', 'Dimethyl fumarate has not been studied in patients with liver dysfunction; although no dosage adjustment is needed, caution is recommended when using dimethyl fumarate in these patients.  Clinically significant cases of liver injury have been reported in patients treated with dimethyl fumarate in the postmarketing setting.  Signs/symptoms of liver injury, including elevation of serum aminotransferases to greater than 5-fold the upper limit of normal (ULN) and elevation of total bilirubin to greater than 2-fold ULN have been observed; these abnormalities resolved upon treatment discontinuation.  Elevations of hepatic transaminases (most no greater than 3 times ULN) were observed during controlled trials.  Serum aminotransferase, alkaline phosphatase, and total bilirubin levels should be obtained prior to and during treatment with dimethyl fumarate, as clinically indicated.  Therapy should be discontinued if clinically significant liver injury induced by dimethyl fumarate is suspected.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47476, 22324, 'Dimethyl fumarate', 'Liver Failure', 'Dimethyl fumarate has not been studied in patients with liver dysfunction; although no dosage adjustment is needed, caution is recommended when using dimethyl fumarate in these patients.  Clinically significant cases of liver injury have been reported in patients treated with dimethyl fumarate in the postmarketing setting.  Signs/symptoms of liver injury, including elevation of serum aminotransferases to greater than 5-fold the upper limit of normal (ULN) and elevation of total bilirubin to greater than 2-fold ULN have been observed; these abnormalities resolved upon treatment discontinuation.  Elevations of hepatic transaminases (most no greater than 3 times ULN) were observed during controlled trials.  Serum aminotransferase, alkaline phosphatase, and total bilirubin levels should be obtained prior to and during treatment with dimethyl fumarate, as clinically indicated.  Therapy should be discontinued if clinically significant liver injury induced by dimethyl fumarate is suspected.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47477, 22325, 'Dimethyl fumarate', 'Liver Failure', 'Dimethyl fumarate has not been studied in patients with liver dysfunction; although no dosage adjustment is needed, caution is recommended when using dimethyl fumarate in these patients.  Clinically significant cases of liver injury have been reported in patients treated with dimethyl fumarate in the postmarketing setting.  Signs/symptoms of liver injury, including elevation of serum aminotransferases to greater than 5-fold the upper limit of normal (ULN) and elevation of total bilirubin to greater than 2-fold ULN have been observed; these abnormalities resolved upon treatment discontinuation.  Elevations of hepatic transaminases (most no greater than 3 times ULN) were observed during controlled trials.  Serum aminotransferase, alkaline phosphatase, and total bilirubin levels should be obtained prior to and during treatment with dimethyl fumarate, as clinically indicated.  Therapy should be discontinued if clinically significant liver injury induced by dimethyl fumarate is suspected.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47478, 27964, 'Dimethyl fumarate', 'Liver Failure', 'Dimethyl fumarate has not been studied in patients with liver dysfunction; although no dosage adjustment is needed, caution is recommended when using dimethyl fumarate in these patients.  Clinically significant cases of liver injury have been reported in patients treated with dimethyl fumarate in the postmarketing setting.  Signs/symptoms of liver injury, including elevation of serum aminotransferases to greater than 5-fold the upper limit of normal (ULN) and elevation of total bilirubin to greater than 2-fold ULN have been observed; these abnormalities resolved upon treatment discontinuation.  Elevations of hepatic transaminases (most no greater than 3 times ULN) were observed during controlled trials.  Serum aminotransferase, alkaline phosphatase, and total bilirubin levels should be obtained prior to and during treatment with dimethyl fumarate, as clinically indicated.  Therapy should be discontinued if clinically significant liver injury induced by dimethyl fumarate is suspected.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47479, 27965, 'Dimethyl fumarate', 'Liver Failure', 'Dimethyl fumarate has not been studied in patients with liver dysfunction; although no dosage adjustment is needed, caution is recommended when using dimethyl fumarate in these patients.  Clinically significant cases of liver injury have been reported in patients treated with dimethyl fumarate in the postmarketing setting.  Signs/symptoms of liver injury, including elevation of serum aminotransferases to greater than 5-fold the upper limit of normal (ULN) and elevation of total bilirubin to greater than 2-fold ULN have been observed; these abnormalities resolved upon treatment discontinuation.  Elevations of hepatic transaminases (most no greater than 3 times ULN) were observed during controlled trials.  Serum aminotransferase, alkaline phosphatase, and total bilirubin levels should be obtained prior to and during treatment with dimethyl fumarate, as clinically indicated.  Therapy should be discontinued if clinically significant liver injury induced by dimethyl fumarate is suspected.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47480, 5824, 'Dimethyl fumarate', 'Lymphopenia', 'The use of dimethyl fumarate may decrease lymphocyte counts.  Dimethyl fumarate has not been studied in patients with preexisting low lymphocyte counts; caution is advised in these patients.  CBC (including lymphocyte count) should be obtained before initiating treatment with dimethyl fumarate, 6 months after starting treatment, every 6 to 12 months thereafter, and as clinically indicated.  Interruption of therapy in patients with lymphocyte counts less than 0.5 x 10(9) cells/L persisting for more than 6 months and withholding treatment from patients with serious infections until resolution should be considered.  Caution is recommended and decisions about whether or not to restart dimethyl fumarate should be individualized based on clinical circumstances.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47481, 22278, 'Dimethyl fumarate', 'Lymphopenia', 'The use of dimethyl fumarate may decrease lymphocyte counts.  Dimethyl fumarate has not been studied in patients with preexisting low lymphocyte counts; caution is advised in these patients.  CBC (including lymphocyte count) should be obtained before initiating treatment with dimethyl fumarate, 6 months after starting treatment, every 6 to 12 months thereafter, and as clinically indicated.  Interruption of therapy in patients with lymphocyte counts less than 0.5 x 10(9) cells/L persisting for more than 6 months and withholding treatment from patients with serious infections until resolution should be considered.  Caution is recommended and decisions about whether or not to restart dimethyl fumarate should be individualized based on clinical circumstances.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47482, 22279, 'Dimethyl fumarate', 'Lymphopenia', 'The use of dimethyl fumarate may decrease lymphocyte counts.  Dimethyl fumarate has not been studied in patients with preexisting low lymphocyte counts; caution is advised in these patients.  CBC (including lymphocyte count) should be obtained before initiating treatment with dimethyl fumarate, 6 months after starting treatment, every 6 to 12 months thereafter, and as clinically indicated.  Interruption of therapy in patients with lymphocyte counts less than 0.5 x 10(9) cells/L persisting for more than 6 months and withholding treatment from patients with serious infections until resolution should be considered.  Caution is recommended and decisions about whether or not to restart dimethyl fumarate should be individualized based on clinical circumstances.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47483, 22324, 'Dimethyl fumarate', 'Lymphopenia', 'The use of dimethyl fumarate may decrease lymphocyte counts.  Dimethyl fumarate has not been studied in patients with preexisting low lymphocyte counts; caution is advised in these patients.  CBC (including lymphocyte count) should be obtained before initiating treatment with dimethyl fumarate, 6 months after starting treatment, every 6 to 12 months thereafter, and as clinically indicated.  Interruption of therapy in patients with lymphocyte counts less than 0.5 x 10(9) cells/L persisting for more than 6 months and withholding treatment from patients with serious infections until resolution should be considered.  Caution is recommended and decisions about whether or not to restart dimethyl fumarate should be individualized based on clinical circumstances.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47484, 22325, 'Dimethyl fumarate', 'Lymphopenia', 'The use of dimethyl fumarate may decrease lymphocyte counts.  Dimethyl fumarate has not been studied in patients with preexisting low lymphocyte counts; caution is advised in these patients.  CBC (including lymphocyte count) should be obtained before initiating treatment with dimethyl fumarate, 6 months after starting treatment, every 6 to 12 months thereafter, and as clinically indicated.  Interruption of therapy in patients with lymphocyte counts less than 0.5 x 10(9) cells/L persisting for more than 6 months and withholding treatment from patients with serious infections until resolution should be considered.  Caution is recommended and decisions about whether or not to restart dimethyl fumarate should be individualized based on clinical circumstances.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47485, 27964, 'Dimethyl fumarate', 'Lymphopenia', 'The use of dimethyl fumarate may decrease lymphocyte counts.  Dimethyl fumarate has not been studied in patients with preexisting low lymphocyte counts; caution is advised in these patients.  CBC (including lymphocyte count) should be obtained before initiating treatment with dimethyl fumarate, 6 months after starting treatment, every 6 to 12 months thereafter, and as clinically indicated.  Interruption of therapy in patients with lymphocyte counts less than 0.5 x 10(9) cells/L persisting for more than 6 months and withholding treatment from patients with serious infections until resolution should be considered.  Caution is recommended and decisions about whether or not to restart dimethyl fumarate should be individualized based on clinical circumstances.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47486, 27965, 'Dimethyl fumarate', 'Lymphopenia', 'The use of dimethyl fumarate may decrease lymphocyte counts.  Dimethyl fumarate has not been studied in patients with preexisting low lymphocyte counts; caution is advised in these patients.  CBC (including lymphocyte count) should be obtained before initiating treatment with dimethyl fumarate, 6 months after starting treatment, every 6 to 12 months thereafter, and as clinically indicated.  Interruption of therapy in patients with lymphocyte counts less than 0.5 x 10(9) cells/L persisting for more than 6 months and withholding treatment from patients with serious infections until resolution should be considered.  Caution is recommended and decisions about whether or not to restart dimethyl fumarate should be individualized based on clinical circumstances.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47487, 5824, 'Dimethyl fumarate', 'Leukoencephalopathy, Progressive Multifocal', 'Progressive multifocal leukoencephalopathy (PML) has occurred in patients with multiple sclerosis (MS) treated with dimethyl fumarate; PML is an opportunistic viral infection of the brain caused by the John Cunningham virus (JC virus) that generally only occurs in immunocompromised patients and usually leads to death or severe disability.  Caution and monitoring are advised in patients with MS.  Dimethyl fumarate should be withheld at the first sign/symptom suggestive of PML and an appropriate diagnostic evaluation should be performed.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47488, 22278, 'Dimethyl fumarate', 'Leukoencephalopathy, Progressive Multifocal', 'Progressive multifocal leukoencephalopathy (PML) has occurred in patients with multiple sclerosis (MS) treated with dimethyl fumarate; PML is an opportunistic viral infection of the brain caused by the John Cunningham virus (JC virus) that generally only occurs in immunocompromised patients and usually leads to death or severe disability.  Caution and monitoring are advised in patients with MS.  Dimethyl fumarate should be withheld at the first sign/symptom suggestive of PML and an appropriate diagnostic evaluation should be performed.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47489, 22279, 'Dimethyl fumarate', 'Leukoencephalopathy, Progressive Multifocal', 'Progressive multifocal leukoencephalopathy (PML) has occurred in patients with multiple sclerosis (MS) treated with dimethyl fumarate; PML is an opportunistic viral infection of the brain caused by the John Cunningham virus (JC virus) that generally only occurs in immunocompromised patients and usually leads to death or severe disability.  Caution and monitoring are advised in patients with MS.  Dimethyl fumarate should be withheld at the first sign/symptom suggestive of PML and an appropriate diagnostic evaluation should be performed.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47490, 22324, 'Dimethyl fumarate', 'Leukoencephalopathy, Progressive Multifocal', 'Progressive multifocal leukoencephalopathy (PML) has occurred in patients with multiple sclerosis (MS) treated with dimethyl fumarate; PML is an opportunistic viral infection of the brain caused by the John Cunningham virus (JC virus) that generally only occurs in immunocompromised patients and usually leads to death or severe disability.  Caution and monitoring are advised in patients with MS.  Dimethyl fumarate should be withheld at the first sign/symptom suggestive of PML and an appropriate diagnostic evaluation should be performed.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47491, 22325, 'Dimethyl fumarate', 'Leukoencephalopathy, Progressive Multifocal', 'Progressive multifocal leukoencephalopathy (PML) has occurred in patients with multiple sclerosis (MS) treated with dimethyl fumarate; PML is an opportunistic viral infection of the brain caused by the John Cunningham virus (JC virus) that generally only occurs in immunocompromised patients and usually leads to death or severe disability.  Caution and monitoring are advised in patients with MS.  Dimethyl fumarate should be withheld at the first sign/symptom suggestive of PML and an appropriate diagnostic evaluation should be performed.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47492, 27964, 'Dimethyl fumarate', 'Leukoencephalopathy, Progressive Multifocal', 'Progressive multifocal leukoencephalopathy (PML) has occurred in patients with multiple sclerosis (MS) treated with dimethyl fumarate; PML is an opportunistic viral infection of the brain caused by the John Cunningham virus (JC virus) that generally only occurs in immunocompromised patients and usually leads to death or severe disability.  Caution and monitoring are advised in patients with MS.  Dimethyl fumarate should be withheld at the first sign/symptom suggestive of PML and an appropriate diagnostic evaluation should be performed.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47493, 27965, 'Dimethyl fumarate', 'Leukoencephalopathy, Progressive Multifocal', 'Progressive multifocal leukoencephalopathy (PML) has occurred in patients with multiple sclerosis (MS) treated with dimethyl fumarate; PML is an opportunistic viral infection of the brain caused by the John Cunningham virus (JC virus) that generally only occurs in immunocompromised patients and usually leads to death or severe disability.  Caution and monitoring are advised in patients with MS.  Dimethyl fumarate should be withheld at the first sign/symptom suggestive of PML and an appropriate diagnostic evaluation should be performed.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47494, 5824, 'Dimethyl fumarate', 'Kidney Diseases', 'Dimethyl fumarate has not been studied in patients with renal dysfunction; although no dosage adjustment is needed, caution is recommended when using dimethyl fumarate in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47495, 22278, 'Dimethyl fumarate', 'Kidney Diseases', 'Dimethyl fumarate has not been studied in patients with renal dysfunction; although no dosage adjustment is needed, caution is recommended when using dimethyl fumarate in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47496, 22279, 'Dimethyl fumarate', 'Kidney Diseases', 'Dimethyl fumarate has not been studied in patients with renal dysfunction; although no dosage adjustment is needed, caution is recommended when using dimethyl fumarate in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47497, 22324, 'Dimethyl fumarate', 'Kidney Diseases', 'Dimethyl fumarate has not been studied in patients with renal dysfunction; although no dosage adjustment is needed, caution is recommended when using dimethyl fumarate in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47498, 22325, 'Dimethyl fumarate', 'Kidney Diseases', 'Dimethyl fumarate has not been studied in patients with renal dysfunction; although no dosage adjustment is needed, caution is recommended when using dimethyl fumarate in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47499, 27964, 'Dimethyl fumarate', 'Kidney Diseases', 'Dimethyl fumarate has not been studied in patients with renal dysfunction; although no dosage adjustment is needed, caution is recommended when using dimethyl fumarate in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (47500, 27965, 'Dimethyl fumarate', 'Kidney Diseases', 'Dimethyl fumarate has not been studied in patients with renal dysfunction; although no dosage adjustment is needed, caution is recommended when using dimethyl fumarate in these patients.', '2', '', 'DDInter', 0);
